Page last updated: 2024-11-13
zorbamycin
Description
zorbamycin: antibiotic related to bleomycin & phleomycin; structure in second source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
zorbamycin : A glycopeptide antibiotic found in Streptomyces flavoviridis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (12)
| Synonym |
|---|
| 11056-20-5 |
| zorbamycin [usan] |
| zorbamycin |
| u-30604 |
| iqz99q218q , |
| u-30,604 |
| unii-iqz99q218q |
| CHEBI:67811 |
| antibiotic derived from streptomyces bikiniensis variant |
| DTXSID80149300 |
| (2r,3s,4s,5r,6r)-2-{[(2r,3s,4s,5s,6s)-2-{[(1r,2s)-2-[({6-amino-2-[(1s)-3-amino-1-{[(2s)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl]-5-methylpyrimidin-4-yl}carbonyl)amino]-3-{[(3r,4s,5s)-6-{[(2s)-1-({2-[(4'r)-4-{[(3e)-3-amino-3-iminopropyl]carbamoyl}-4',5' |
| Q27136288 |
Research Excerpts
Overview
Zorbamycin is a glycopeptide antitumor antibiotic first reported in 1971.
| Excerpt | Reference | Relevance |
|---|
| "Zorbamycin (1, ZBM) is a glycopeptide antitumor antibiotic first reported in 1971. " | ( Glycopeptide antitumor antibiotic zorbamycin from Streptomyces flavoviridis ATCC 21892: strain improvement and structure elucidation.
Coughlin, JM; Galm, U; George, NP; Oh, TJ; Shen, B; Tao, M; Wang, L; Wendt-Pienkowski, E; Yun, BS; Zhang, G, 2007) | 2.06 |
Roles (2)
| Role | Description |
|---|
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
| Class | Description |
|---|
| glycopeptide | Any carbohydrate derivative that consists of glycan moieties covalently attached to the side chains of the amino acid residues that constitute the peptide. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.51
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.51 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 4.59 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |